Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GZTC -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (691)	3/24/2000 11:09:00 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 752

<<Tumor growth is dependent upon the balance of positive and negative regulators of angiogenesis.>> Why will cancer cells generate/produce anti-angiogenic protein? Yan postulated this (not only for Angio-1 or -2) for many angiogenic/anti-angiogenic proteins two years ago. Depend on the environment and micro-conditions (presence of other regulators, stage and progress of the tumor-vasculature, genotype, ...) each of this proteins have positive and negative angiogenic characteristic. My best bets is that certain angio-proteins will have limited utility in cancer therapy, if at all. Certain downstream intracellular targets with well define biology and specificity for cancer cells growth are for now what may work for cancer, imo. At this point we do have some good results for membrane receptors as target, but hetero- and/or multiple-dimerization (where antibody miss their activity and specificity) and alternative activation and/or signaling may induce resistance and therapy failure.